Friday, 16 October 2026European Markets

PGS Stock Is 9% Down At Session Start Today

Loading stream...

(VIANEWS) - Shares of PGS (Oslo Børs Benchmark Index_GI: PGS.OL) fell 9.06% to kr8.78 at 10:39 EST on Monday, after two successive sessions in a row of gains. Oslo Børs Benchmark Index_GI is sliding 1.99% to kr1,130.05, after five consecutive sessions in a row of losses. This seems, up until now, an all-around bearish trend exchanging session today.

PGS's last close was kr9.66, 26.54% below its 52-week high of kr13.15.

About PGS

PGS ASA, together with its subsidiaries, operates as a marine geophysical company primarily in Norway. The company provides a range of seismic and reservoir services, including data acquisition, imaging, interpretation, and field evaluation to oil and gas companies. It also operates in the Asia Pacific, Canada, Egypt, the Americas, Angola, the United Kingdom, Ukraine, Brazil, South Africa, other African countries, the Middle East, and internationally. The company was formerly known as Petroleum Geo-Services ASA and changed its name to PGS ASA in May 2019. PGS ASA was founded in 1991 and is headquartered in Oslo, Norway.

Earnings Per Share

As for profitability, PGS has a trailing twelve months EPS of kr-5.26.

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is negative -8.68%.

Volume

Today's last reported volume for PGS is 18851269 which is 11.48% below its average volume of 21296600.

Moving Average

PGS's value is below its 50-day moving average of kr9.45 and way above its 200-day moving average of kr7.43.

Yearly Top and Bottom Value

PGS's stock is valued at kr8.78 at 10:39 EST, way below its 52-week high of kr13.15 and way above its 52-week low of kr2.58.

More news about PGS (PGS.OL).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com